Lisata-Kuva Merger Delayed Again; $1.5M Option for August Extension
LSTA sits 86% above its 52-week low of $1.81 on light trading volume (0.3× avg).
Summary
Lisata Therapeutics and Kuva Labs have again amended their merger agreement, extending the "Outside Date" to July 17, 2026. Kuva Labs has an option to further extend to August 17, 2026, by paying a non-refundable $1.5 million. This follows a series of delays and previous amendments to the critical merger, which is essential for Lisata given its going concern warning issued in May. The ongoing financing uncertainty for Kuva Labs continues to cast doubt on the acquisition's completion, posing a significant risk to Lisata's future. The market will be watching for the tender offer commencement on June 10th.
At the time of this announcement, LSTA was trading at $3.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.7M. The 52-week trading range was $1.81 to $5.07. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.